Plain English Summary
Background and study aims
How well the antibiotic meropenem works depends on the dose used. The aim of this study was to compare the benefits of continuous infusion of meropenem against bolus administration (large dose given by injection in bloodstream to achieve the desired level rapidly), in critically ill patients, with severe infection.
Who can participate?
Patients aged 18 years or older (both men and women), admitted to the intensive care unit (ICU) of the university hospital, who suffered from severe infection .
What does the study involve?
Comparing continuous infusion of meropenem versus intermittent administration of meropenem given in higher daily dose. Patients were were randomly allocated to the Infusion group or the Bolus group.
What are the possible benefits and risks of participating?
We presumed that continuous infusion of meropenem could provide the same or better clinical and microbiological efficacy than intermittent administration of meropenem given in higher daily dose.
There were no additional risks in both groups.
Where is the study run from?
Department of Anesthesiology and Intensive Care Medicine at Charles University teaching hospital in Plzen, Czech Republic.
When is study starting and how long is it expected to run for?
The study started on 01/10/2007 and ended on 30/04/2010.
Who is funding the study?
Czech Ministry of Education (project ref: MSM0021620819).
Who is the main contact?
Dr Ivan Chytra
chytra@fnplzen.cz
Trial website
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
N/A
Study information
Scientific title
Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized prospective single center study
Acronym
Study hypothesis
Meropenem bactericidal activity depends on the time when the free drug concentrations remain above the minimum inhibitory concentration (MIC) of pathogens. In conventional bolus dosing regimens serum concentrations of meropenem between doses can fall to lower concentrations than MIC of less susceptible pathogens. We presume that continuous infusion of meropenem can provide the same or better clinical and microbiological efficacy than intermittent administration of meropenem given in higher daily dose.
Ethics approval
Local Research Ethics Committee of University Hospital in Plzen, 17 May 2007
Study design
Single-center prospective randomized open-label comparative study
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Condition
Critically ill patients with severe infection
Intervention
Patients admitted to the intensive care (ICU) of university hospital who suffered from severe infection and received meropenem were randomized either in the Infusion group or in the Bolus group.
Patients in the Infusion group received loading dose of 2g of meropenem followed by continuous infusion of 4g of meropenem over 24 hours.
Patients in the Bolus group were given 2g of meropenem over 30 minutes every 8 hours.
Clinical and microbiological outcome, meropenem-related length of ICU and hospital stay, meropenem-related length of mechanical ventilation, duration of meropenem treatment, total dose of meropenem, ICU and in-hospital mortality, safety and cost effectiveness were assessed.
Patients were followed up to hospital discharge.
Intervention type
Other
Phase
Not Applicable
Drug names
Primary outcome measures
1. Clinical and microbiological efficacy of meropenem therapy were evaluated at the end of meropenem therapy
Clinical response was evaluated at the end of therapy as treatment success or failure. Clinical success was defined as complete or partial resolution of leukocytosis, temperature, and clinical signs and symptoms of infection. Cure was defined as complete resolution of all acute signs and symptoms of infection, with no new signs or symptoms associated with the original infection. Patients who retained evidence of infection but demonstrated a reduction of the majority of the clinical signs and symptoms of infection and no new or worsened signs associated with the original infection were classified as improved. For the purpose of statistical analysis, patients meeting the definitions of cured and improved were combined and defined as clinical successes. Failure consisted of any of the following:
1.1. Persistence or progression of signs and symptoms of infection
1.2. Development of new clinical findings consistent with active infection
1.3. Death from infection
2. Microbiological outcome was assigned one of the following categories: eradication, presumed eradication, persistence, presumed persistence, resistance or unevaluable. Eradication was defined as elimination of the pathogen from the site of isolation. Presumed eradication consisted of absence of appropriate material for culture or absence of results of control microbiological tests coupled with clinical improvement after a pathogen was initially isolated. Three possible outcomes were defined collectively as persistence: verified persistence (failure to eradicate the original pathogen from the site of isolation after completion of therapy), presumed persistence (absence of appropriate material for culture or absence of results of control microbiological tests coupled with lack of clinical improvement after a pathogen was initially isolated) and development of resistance during therapy. Patients without cultures or evident pathogens from the presumed site of infection were deemed unevaluable.The categories of eradication and presumed eradication were combined and defined as microbiologic success. Persistence was designated as microbiologic failure.
Secondary outcome measures
1. Meropenem-related length of mechanical ventilation
2. Meropenem-related length of ICU and hospital stay (LOS)
3. ICU and in-hospital mortality
4. Duration of meropenem treatment
5. The total dose of meropenem
6. Safety and cost effectiveness of both dosing regimens
Overall trial start date
01/10/2007
Overall trial end date
30/04/2010
Reason abandoned
Eligibility
Participant inclusion criteria
1. Patients aged 18 years and over
2. Admitted to the interdisciplinary Intensive Care Unit (ICU) between September 2007 and May 2010
3. Had suffered from severe infection and received meropenem with predicted duration of treatment for at least 4 days at the admission or during the ICU stay
4. Types of infections include:
4.1. Abdominal
4.2. Respiratory
4.3. Skin
4.4. Soft tissue
4.5. Bloodstream
4.6. Central nervous system
4.7. Urinary tract
4.8. Other sources of infections
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
Target number of participants was 240
Participant exclusion criteria
1. Age younger than 18 years
2. Pregnancy
3. Acute or chronic renal failure with glomerular filtration rate lower than 0.5 ml/s
4. Immunodeficiency or immunosuppressant medication
5. Neutropenia
6. Hypersensitivity or allergy to meropenem
Recruitment start date
01/10/2007
Recruitment end date
30/04/2010
Locations
Countries of recruitment
Czech Republic
Trial participating centre
Department of Anesthesia and Intensive Care
Plzen
30460
Czech Republic
Sponsor information
Organisation
Charles University Teaching Hospital Plzen (Czech Republic)
Sponsor details
Department of Anesthesia and Intensive Care
Alej Svobody 80
Plzen
304 60
Czech Republic
+420 377 104 384
chytra@fnplzen.cz
Sponsor type
Hospital/treatment centre
Website
Funders
Funder type
Government
Funder name
Czech Ministry of Education (Czech Republic) ref: MSM0021620819
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Results - basic reporting
Publication summary